Travere Therapeutics (TVTX) Receivables - Net (2016 - 2025)
Travere Therapeutics (TVTX) has disclosed Receivables - Net for 12 consecutive years, with $80.1 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Receivables - Net rose 195.52% year-over-year to $80.1 million, compared with a TTM value of $80.1 million through Dec 2025, up 195.52%, and an annual FY2025 reading of $80.1 million, up 195.52% over the prior year.
- Receivables - Net was $80.1 million for Q4 2025 at Travere Therapeutics, down from $83.0 million in the prior quarter.
- Across five years, Receivables - Net topped out at $83.0 million in Q3 2025 and bottomed at $11.9 million in Q2 2021.
- Average Receivables - Net over 5 years is $26.4 million, with a median of $20.8 million recorded in 2023.
- The sharpest move saw Receivables - Net decreased 27.62% in 2021, then soared 229.76% in 2025.
- Year by year, Receivables - Net stood at $15.9 million in 2021, then grew by 4.6% to $16.6 million in 2022, then increased by 27.23% to $21.2 million in 2023, then grew by 28.03% to $27.1 million in 2024, then skyrocketed by 195.52% to $80.1 million in 2025.
- Business Quant data shows Receivables - Net for TVTX at $80.1 million in Q4 2025, $83.0 million in Q3 2025, and $38.7 million in Q2 2025.